Gene expression markers for inflammatory bowel disease
OwnerAlexander R. Abbas, Lauri Diehl +3inventors
InventorsAlexander R. Abbas, Lauri Diehl, Charles Lees, Colin L. Noble, Jack Satsangi
Life of this patent
Estimating the term…
Abstract
The present invention provides for a method of detecting the presence of inflammatory bowel disease in gastrointestinal tissues or cells of a mammal by detecting decreased expression of Indian Hedgehog (Ihh) and/or increased expression of Defensin A5 (DefA5) and/or Defensin A6 (DefA6) in the tissues or cells of the mammal relative to a control.
Claims43
A method of diagnosing the presence of an inflammatory bowel disease (IBD) in a mammalian subject, comprising
- (a) determining that a level of expression of a nucleic acid encoding a polypeptide shown as SEQ ID NO:2 in a test sample obtained from said subject is lower relative to a level of expression in a control, wherein said lower level of expression is indicative of the presence of an IBD in the subject from which the test sample was obtained.
A method of diagnosing the presence of an inflammatory bowel disease (IBD) in a mammalian subject, comprising
- (a) determining that a level of expression of a nucleic acid encoding a polypeptide shown as SEQ ID NO:4 and/or a polypeptide shown as SEQ ID NO:6 in a test sample obtained from said subject is higher relative to a level of expression in a control, wherein said higher level of expression is indicative of the presence of an IBD in the subject from which the test sample was obtained.
A method of diagnosing the presence of an inflammatory bowel disease (IBD) in a mammalian subject, comprising
- (a) determining that a level of expression of a nucleic acid encoding a polypeptide shown as SEQ ID NO:2 in a first test sample obtained from said subject is lower relative to the level of expression in a first control, wherein said lower level of expression is indicative of the presence of an IBD in the subject from which the first test sample was obtained;
- and
- (b) determining that a level of expression of a nucleic acid encoding a polypeptide shown as SEQ ID NO:4 and/or a polypeptide shown as SEQ ID NO:6 in a second test sample obtained from said subject is higher relative to the level of expression in a second control, wherein said higher level of expression is indicative of the presence of an IBD in the subject from which the second test sample was obtained.
A method of treating an inflammatory bowel disease (IBD) in a mammalian subject in need thereof, the method comprising the steps of
- (a) determining that a level of expression of a nucleic acid encoding a polypeptide shown as SEQ ID NO:2 in a test sample obtained from said subject is lower relative to a level of expression in a control, wherein said lower level of expression is indicative of the presence of an IBD in the subject from which the test sample was obtained;
- and
- (b) administering to said subject an effective amount of an IBD therapeutic agent.
A method of treating an inflammatory bowel disease (IBD) in a mammalian subject in need thereof, the method comprising the steps of
- (a) determining that a level of expression of a nucleic acid encoding a polypeptide shown as SEQ ID NO:4 and/or a polypeptide shown as SEQ ID NO:6 in a test sample obtained from said subject is higher relative to a level of expression in a control, wherein said higher level of expression is indicative of the presence of an IBD in the subject from which the test sample was obtained;
- and
- (b) administering to said subject an effective amount of an IBD therapeutic agent.
A method of treating an inflammatory bowel disease (IBD) in a mammalian subject, comprising
- (a) determining that a level of expression of a nucleic acid encoding a polypeptide shown as SEQ ID NO:2 in a first test sample obtained from said subject is lower relative to a level of expression in a first control, wherein said lower level of expression is indicative of the presence of an IBD in the subject from which the first test sample was obtained;
- (b) determining that a level of expression of a nucleic acid encoding a polypeptide shown as SEQ ID NO:4 and/or a polypeptide shown as SEQ ID NO:6 in a second test sample obtained from said subject is higher relative to a level of expression in a second control, wherein said higher level of expression is indicative of the presence of an IBD in the subject from which the second test sample was obtained;
- and
- (c) administering to said subject an effective amount of an IBD therapeutic agent.
Dependencies are inferred from the claim text.